zoom_in Click to enlarge

Tasuku Honjo

▲ ▼

description Tasuku Honjo Overview

Tasuku Honjo is a Japanese immunologist recognized for his groundbreaking research into the regulation of the immune system. His work identified PD-1, an inhibitory receptor that acts as a crucial ‘brake’ on T cells, significantly impacting cancer immunotherapy development. This discovery earned him and James Allison the 2018 Nobel Prize in Physiology or Medicine. Honjo's research is primarily relevant to oncologists, immunologists, and researchers investigating novel treatments for cancers, particularly those utilizing immune checkpoint blockade therapies.

help Tasuku Honjo FAQ

What is the PD-1 receptor discovered by Tasuku Honjo?

Tasuku Honjo discovered the Programmed Cell Death Protein 1 (PD-1) receptor on the surface of T-cells in 1992. He proved that this specific receptor acts as an immune checkpoint, applying a biological brake that stops T-cells from attacking healthy cells.

How did Tasuku Honjo's PD-1 discovery change cancer treatment?

His discovery directly led to the clinical development of a new class of drugs called immune checkpoint inhibitors. These drugs, such as nivolumab and pembrolizumab, work by blocking the PD-1 brake, allowing the patient's immune system to effectively attack tumors.

When did Tasuku Honjo receive the Nobel Prize for his work on PD-1?

Tasuku Honjo was awarded the Nobel Prize in Physiology or Medicine in 2018. He shared the award with American immunologist James P. Allison, who independently discovered a similar immune brake known as CTLA-4.

What specific types of cancers are treated successfully using PD-1 inhibitors developed from Honjo's research?

PD-1 inhibitors have proven highly effective against previously hard-to-treat cancers, particularly metastatic melanoma and non-small cell lung cancer. These therapies have fundamentally altered oncology protocols since their clinical approval in the mid-2010s.